NASDAQ:CYTK - Cytokinetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.67
  • Forecasted Upside: 83.30 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$16.73
▲ +0.14 (0.84%)
1 month | 3 months | 12 months
Get New Cytokinetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$30.67
▲ +83.30% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $30.67, with a high forecast of $48.00 and a low forecast of $16.00. The average price target represents a 83.30% upside from the last price of $16.73.
Buy
The current consensus among 9 polled investment analysts is to buy stock in Cytokinetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/24/2020Raymond JamesReiterated RatingBuyHigh
i
Rating by Dane Leone at Raymond James
11/23/2020HC WainwrightLower Price TargetBuy$43.00 ➝ $22.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/16/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
i
Rating by Chad Messer at Needham & Company LLC
11/16/2020Morgan StanleyLower Price TargetOverweight$24.00 ➝ $22.00High
i
10/28/2020The Goldman Sachs GroupInitiated CoverageNeutral$16.00Low
i
10/12/2020Morgan StanleyLower Price TargetOverweight$35.00 ➝ $24.00Low
i
10/8/2020HC WainwrightLower Price TargetPositive ➝ Buy$59.00 ➝ $43.00High
i
Rating by Joseph Pantginis at HC Wainwright
10/6/2020Cantor FitzgeraldBoost Price TargetOverweight$41.00 ➝ $48.00Medium
i
7/23/2020Piper SandlerBoost Price TargetOverweight$33.00 ➝ $36.00Low
i
7/23/2020HC WainwrightBoost Price TargetBuy$38.00 ➝ $59.00Low
i
Rating by Joseph Pantginis at HC Wainwright
7/15/2020Cantor FitzgeraldBoost Price TargetOverweight$29.00 ➝ $41.00High
i
7/15/2020JMP SecuritiesBoost Price TargetOutperform$23.00 ➝ $29.00High
i
7/14/2020Needham & Company LLCBoost Price TargetBuy$34.00 ➝ $45.00High
i
Rating by Chad Messer at Needham & Company LLC
7/14/2020Piper SandlerBoost Price Target$28.00 ➝ $33.00High
i
7/14/2020HC WainwrightBoost Price TargetBuy$35.00 ➝ $38.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00High
i
7/7/2020Morgan StanleyBoost Price TargetOverweight$29.00 ➝ $35.00High
i
5/23/2020MizuhoInitiated CoverageBuy$31.00Low
i
Rating by Salim Syed at Mizuho
5/12/2020Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $29.00Low
i
5/11/2020HC WainwrightBoost Price TargetPositive ➝ Buy$30.00 ➝ $35.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/7/2020Needham & Company LLCReiterated RatingBuy$24.00Low
i
Rating by Chad Messer at Needham & Company LLC
5/4/2020MizuhoInitiated CoverageBuy$31.00High
i
4/27/2020Morgan StanleyReiterated RatingBuy$25.00Low
i
4/24/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by Joseph Pantginis at HC Wainwright
4/19/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
i
4/17/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $23.00High
i
4/14/2020HC WainwrightReiterated RatingBuy$30.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
4/14/2020Needham & Company LLCReiterated RatingBuy$24.00Low
i
Rating by Chad Messer at Needham & Company LLC
4/9/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$14.00 ➝ $25.00High
i
3/31/2020HC WainwrightReiterated RatingBuy$30.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/4/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
i
Rating by Chad Messer at Needham & Company LLC
2/26/2020HC WainwrightReiterated RatingBuy$30.00Low
i
Rating by Joseph Pantginis at HC Wainwright
2/7/2020HC WainwrightReiterated RatingBuyHigh
i
11/1/2019Needham & Company LLCReiterated RatingBuy$24.00High
i
Rating by Chad Messer at Needham & Company LLC
10/4/2019Needham & Company LLCReiterated RatingBuy$16.00Low
i
Rating by Chad Messer at Needham & Company LLC
10/4/2019HC WainwrightReiterated RatingBuy$26.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
9/16/2019Piper Jaffray CompaniesReiterated RatingOverweight$14.00 ➝ $20.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/13/2019JMP SecuritiesSet Price TargetBuy$23.00Medium
i
9/6/2019Cantor FitzgeraldReiterated RatingOverweight$14.00 ➝ $20.00Medium
i
8/9/2019Needham & Company LLCSet Price TargetBuy$16.00Medium
i
Rating by Chad Messer at Needham & Company LLC
8/9/2019Morgan StanleySet Price TargetHold$16.00Medium
i
Rating by Jeffrey Hung at Morgan Stanley
7/15/2019Morgan StanleySet Price TargetHold$11.00High
i
Rating by Jeffrey Hung at Morgan Stanley
7/15/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
5/10/2019Cantor FitzgeraldReiterated RatingBuy$14.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
5/6/2019HC WainwrightBoost Price TargetBuy$21.00 ➝ $26.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
4/23/2019HC WainwrightSet Price TargetBuy$21.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$12.00 ➝ $13.00High
i
3/19/2019HC WainwrightReiterated RatingBuy$21.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/22/2019HC WainwrightReiterated RatingBuy$21.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
12/5/2018HC WainwrightSet Price TargetBuy$21.00Low
i
Rating by Joseph Pantginis at HC Wainwright
12/5/2018Cantor FitzgeraldReiterated RatingBuy$14.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
11/27/2018HC WainwrightReiterated RatingBuy$21.00Low
i
Rating by Joseph Pantginis at HC Wainwright
11/2/2018HC WainwrightSet Price TargetBuy$21.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/2/2018Cantor FitzgeraldSet Price TargetBuy$14.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
10/17/2018HC WainwrightSet Price TargetBuy$21.00High
i
Rating by Joseph Pantginis at HC Wainwright
10/17/2018Cantor FitzgeraldSet Price TargetBuy$14.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
10/5/2018HC WainwrightLower Price TargetBuy ➝ Buy$24.00 ➝ $21.00Low
i
Rating by Joseph Pantginis at HC Wainwright
10/5/2018Morgan StanleySet Price TargetHold$10.00High
i
Rating by Jeffrey Hung at Morgan Stanley
10/3/2018Cantor FitzgeraldReiterated RatingBuy$14.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
9/20/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$14.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/10/2018Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$10.00Medium
i
8/1/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$18.00 ➝ $9.00High
i
7/27/2018HC WainwrightSet Price TargetBuy$24.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/18/2018HC WainwrightBoost Price TargetBuy$24.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/18/2018Piper Jaffray CompaniesLower Price TargetOverweight$13.00High
i
6/17/2018Cantor FitzgeraldReiterated RatingHold$10.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
4/27/2018HC WainwrightReiterated RatingBuy$20.00High
i
Rating by Joseph Pantginis at HC Wainwright
4/24/2018Cantor FitzgeraldSet Price TargetHold$10.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
2/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $18.00High
i
2/20/2018CowenReiterated RatingBuy$11.00Medium
i
2/12/2018Cantor FitzgeraldSet Price TargetHold$10.00Low
i
Rating by M. Goldstein at Cantor Fitzgerald
1/19/2018HC WainwrightSet Price TargetBuy$20.00High
i
Rating by J. Pantginis at HC Wainwright
1/17/2018Cantor FitzgeraldReiterated RatingHold$10.00Low
i
Rating by M. Goldstein at Cantor Fitzgerald
11/29/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00Low
i
11/22/2017Morgan StanleyReiterated RatingOverweight ➝ Overweight$25.00 ➝ $17.00N/A
i
11/22/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$21.00 ➝ $10.00N/A
i
Rating by M. Goldstein at Cantor Fitzgerald
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 ➝ $13.00N/A
i
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/A
i
11/21/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00N/A
i
11/21/2017HC WainwrightLower Price TargetBuy ➝ Buy$26.00 ➝ $17.00N/A
i
Rating by J. Pantginis at HC Wainwright
10/29/2017Needham & Company LLCReiterated RatingBuy$22.00N/A
i
10/27/2017HC WainwrightReiterated RatingBuy$26.00N/A
i
Rating by J. Pantginis at HC Wainwright
10/6/2017Morgan StanleyReiterated RatingOverweight$24.00 ➝ $25.00N/A
i
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$24.00N/A
i
Rating by V. Bernardino at Seaport Global Securities
9/26/2017Cantor FitzgeraldReiterated RatingBuy$21.00Medium
i
Rating by M. Goldstein at Cantor Fitzgerald
9/20/2017HC WainwrightReiterated RatingBuy$26.00Low
i
Rating by Joseph Pantginis at HC Wainwright
9/18/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
i
Rating by M. Goldstein at Cantor Fitzgerald
9/17/2017Needham & Company LLCReiterated RatingBuy$22.00Low
i
8/4/2017CowenReiterated RatingBuy$19.00Low
i
8/3/2017HC WainwrightSet Price TargetBuy$26.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/31/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$24.00High
i
5/19/2017Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by M. Goldstein at Cantor Fitzgerald
4/29/2017CowenReiterated RatingOutperform$17.00 ➝ $19.00Low
i
4/25/2017HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00Medium
i
3/13/2017HC WainwrightReiterated RatingBuyLow
i
3/8/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$25.00High
i
2/17/2017Cantor FitzgeraldReiterated RatingOverweight$21.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/A
i
Rating by Vernon Bernardino at FBR & Co
2/17/2017Needham & Company LLCReiterated RatingStrong-Buy$22.00N/A
i
Rating by chad messer at Needham & Company LLC
2/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/6/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$17.00 ➝ $22.00N/A
i
Rating by chad messer at Needham & Company LLC
2/4/2017FBR & CoSet Price TargetBuy$24.00N/A
i
Rating by Vernon Bernardino at FBR & Co
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$21.00N/A
i
12/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
12/12/2016FBR & CoSet Price TargetBuy$24.00N/A
i
Rating by Vernon Bernardino at FBR & Co
12/1/2016FBR & CoReiterated RatingBuyN/A
i
Rating by Vernon Bernardino at FBR & Co
12/1/2016JMP SecuritiesReiterated RatingBuyN/A
i
10/31/2016CowenReiterated RatingOutperform$16.00N/A
i
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/21/2016Roth CapitalReiterated RatingBuy$22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/5/2016CowenReiterated RatingOutperform$16.00N/A
i
9/9/2016FBR & CoReiterated RatingBuyN/A
i
Rating by Vernon Bernardino at FBR & Co
9/1/2016Needham & Company LLCReiterated RatingBuy$17.00N/A
i
Rating by chad messer at Needham & Company LLC
8/18/2016Roth CapitalReiterated RatingBuy$22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
8/2/2016JMP SecuritiesReiterated RatingBuy$17.00N/A
i
7/27/2016Needham & Company LLCBoost Price TargetBuy$15.00 ➝ $17.00N/A
i
7/13/2016FBR & CoReiterated RatingOutperform$24.00N/A
i
Rating by Vernon Bernardino at FBR & Co
7/12/2016Piper Jaffray CompaniesReiterated RatingOverweight$24.00N/A
i
6/21/2016FBR & CoReiterated RatingBuy$24.00N/A
i
5/25/2016Piper Jaffray CompaniesReiterated RatingOverweight$24.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
5/2/2016FBR & CoReiterated RatingBuyN/A
i
4/30/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Joseph Pantginis at Roth Capital
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 ➝ $14.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 ➝ $14.00N/A
i
2/23/2016Roth CapitalReiterated RatingBuy$22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
2/17/2016CowenReiterated RatingBuy$16.00N/A
i
Rating by Benji Star at Cowen Inc
1/20/2016Roth CapitalReiterated RatingBuy$22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
1/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$24.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
12/16/2015Piper Jaffray CompaniesReiterated RatingBuy$17.00 ➝ $24.00N/A
i
(Data available from 11/27/2015 forward)
Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $16.73
$16.66
$16.96

50 Day Range

MA: $16.46
$15.26
$27.66

52 Week Range

Now: $16.73
$8.00
$30.14

Volume

4,371 shs

Average Volume

1,114,786 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47